Category - Feature

Feature

Soricimed’s platform of unique peptides making waves in cancer and beyond

Closely-held Soricimed Biopharma has developed a first-in-class platform of synthetic peptides whose various targets include an “oncochannel” implicated in the development and progression of many forms of cancer.

October 29, 2019

Feature

Salarius Pharmaceuticals targeting epigenetic causes of cancers

Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the treatment of Ewing sarcoma and advanced...

October 22, 2019

Feature

KemPharm sees license deal, debt restructuring as transformative events

KemPharm (NASDAQ:KMPH) hit a home run last month when it inked a transformative licensing deal of up to $493-million with an affiliate of Gurnet Point Capital, a private equity firm focused on the life science sector...

October 15, 2019

Feature

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

OncoSec Medical (NASDAQ:ONCS) is developing its TAVO drug candidate to enhance local delivery and uptake of DNA-based interleukin-12 (IL-12) directly into solid tumors to reverse patients’ resistance to checkpoint...

October 8, 2019

Feature

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

As a co-founder and CEO of closely-held Incuvers, an early-stage life sciences company developing a sophisticated incubator for cellular biologists, Sebastian Hadjiantoniou knows firsthand the rocky journey from...

October 1, 2019

Feature

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead to neurodegenerative...

September 24, 2019

Feature

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient...

September 10, 2019

Feature

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Closely-held Interface Biologics is selling its Endexo surface modification business and shifting its focus to its Epidel drug delivery technology, initially for ophthalmic indications.

September 3, 2019

Feature

Precipio aims to prevent misdiagnosis of blood-related cancers

Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...

August 27, 2019

Feature

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

Beyond Air (NASDAQ:XAIR), formerly AIT Therapeutics, is developing a proprietary nitric oxide (NO) generator and delivery system that uses NO generated from ambient air, rather than bulky cylinders, and delivers precise...

August 20, 2019

Category - Feature

Soricimed’s platform of unique peptides making waves in cancer and beyond

Salarius Pharmaceuticals targeting epigenetic causes of cancers

KemPharm sees license deal, debt restructuring as transformative events

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Precipio aims to prevent misdiagnosis of blood-related cancers

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

General

More